Drug or technology

Zongertinib

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 19, 2026 · PHASE 2 TRIAL

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

ClinicalTrials.gov

This is an ongoing Phase 2 trial registration with no results reported; it describes a planned study of tolerability in a molecularly defined but small population, which cannot yet inform clinical practice.

PreliminaryZongertinib Lung Cancer, Non Squamous, Non Small Cell Cisplatin

Reported

Planned enrollment60

Phase2

Primary outcome measureOccurrence of discontinuation and/or prolon…

AUG 13, 2026 · PHASE 3 TRIAL

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

ClinicalTrials.gov

This is a Phase 3 trial registration with no posted results; the study is actively recruiting and outcome data are not yet available for analysis.

PreliminaryZongertinib Atezolizumab Pembrolizumab

Reported

Planned enrollment400

PhasePhase 3

Primary outcome measureDisease-free survival (DFS) by investigator…